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Abstract 
 
The article presents the results of cluster analysis 
of the contribution of immune inflammation and 
endothelial dysfunction (ED) markers to the 
frequency and severity of cardiovascular events 
(CVE) in cohorts of patients with asymptomatic 
atherosclerosis (AAS), coronary artery disease 
(CAD), type 2 diabetes mellitus (T2DM) and 
metabolic syndrome (MS) during a 3-year 
prospective observation.  
Results Circulating markers of ED and immune 
inflammation, such as ET-1, IL-1β, TNF-α, 
antibodies to collagen type I and III, and 
antibodies to chondroitine sulfate (CS) contribute 
to cardiovascular (CV) manifestation in AAS. In 
CAD patients ET-1, eNOs, antibodies to collagen, 
as well as IL-6 and vWf  are the main 
contributors. In T2DM without clinical 
manifestation of CAD, the set of markers 
associated with the adverse events includes ET-1, 
eNOs, IL-6, anti-C, and anti-HA. In CAD 
combined with T2DM, the cluster of markers 
associated with the adverse events includes vWf, 
TNF-α, eNOs, IL-6, anti-C, anti-HA and CRP. In 
AAS without MS, the key contributors are ET-1 
   
Анотація 
 
В статье представлены результаты 
кластерного анализа вклада маркеров 
иммунного воспаления и эндотелиальной 
дисфункции (ЭД) в частоту и тяжесть 
сердечно-сосудистых событий в когортах 
пациентов с бессимптомным атеросклерозом 
(AAS), ишемической болезнью сердца, 
сахарным диабетом 2 типа (СД 2-го типа) и 
метаболическим синдромом (МС) в течение 
3-летнего проспективного наблюдения. 
Циркулирующие маркеры ЭД и иммунного 
воспаления, такие как ET-1, IL-1β, TNF-α, 
антитела к коллагену I и III типов и антитела 
к хондроитинсульфату (CS) способствуют 
проявлению сердечно-сосудистых 
заболеваний (ССЗ) при ААС. У больных ИБС 
основными факторами являются ET-1, eNOs, 
антитела к коллагену, а также IL-6 и vWf. При 
СД 2-го типа без клинической манифестации 
ИБС набор маркеров, ассоциированных с 
побочными явлениями, включает ET-1, eNOs, 
IL-6, anti-C, и anti-HA. При ИБС в сочетании 
с СД2, кластер маркеров, ассоциированных с 
негативным событиям относятся vWf, TNF-α, 
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and vWf, and the presence of anti-C and anti-
ChS; in AAS/MS patients, the key markers are 
IL-1β, TNF-α, anti-C, anti-ChS, anti-HA, and 
CRP. In CAD without MS, the cluster of markers 
associated with adverse events includes ET-1, 
eNOs and anti-HA; in CAD/MS it includes anti-
C, ET-1, and IL-6. 
Conclusion. The obtained results confirm the 
role of systemic inflammation in the development 
of atherosclerosis-associated angiopathy in 
coronary pathology and disorders of carbohydrate 
metabolism, and also suggest a set of circulating 
markers as predictors of adverse CVE. 
 
Keywords: Endothelial dysfunction, immune 
inflammation, cytokines, autoantibodies, 
atherosclerosis, ischemic heart disease, coronary 
artery disease, diabetes mellitus, metabolic 
syndrome. 
 
eNOs, IL-6, anti-C, anti-HA и CRP. При ААС 
без МС ключевыми факторами являются ET-
1 и vWf, а также наличие anti-C и anti-ChS; у 
пациентов с ААС/МС ключевыми маркерами 
являются IL-1β, TNF-α, anti-C, anti-ChS, anti-
HA и CRP. При ИБС без МС кластер 
маркеров, ассоциированных с 
неблагоприятными явлениями, включает ET-
1, eNOs и anti-HA; при ИБС/МС он включает 
anti-C, ET-1 и IL-6. 
Полученные результаты подтверждают роль 
системного воспаления в развитии 
атеросклероз-ассоциированной ангиопатии 
при коронарной патологии и нарушениях 
углеводного обмена, а также предполагают 
набор циркулирующих маркеров в качестве 
предикторов неблагоприятных сердечно-
сосудистых событий. 
 
Ключевые слова: эндотелиальная 
дисфункция, иммунное воспаление, 
цитокины, аутоантитела, атеросклероз, 
ишемическая болезнь сердца, болезнь 
коронарной артерии, сахарный диабет, 
метаболический синдром. 
 
Introduction 
 
Atherosclerosis and CAD are some of the major 
global health problems today with highly 
unfavorable contribution to demographic 
indicators [Russian Statistical Yearbook, 2017]. 
The prevalence of atherosclerosis-associated 
diseases is increasing, although the death rate 
from CAD has significantly decreased in recent 
decades due to introduction of modern 
algorithms for early diagnosis and effective 
treatment [Russian Statistical Yearbook, 2017]. 
Another serious medical and social problem is 
diabetes mellitus (DM), which leads to vascular 
complications resulting in reduced quality of life 
and increased mortality. In particular, 
atherosclerotic angiopathies (first of all, CAD, 
myocardial infarction, chronic heart failure, and 
cerebral stroke) account for up to 80% of adverse 
outcomes in patients with T2DM [Algorithms…, 
2017; de Rooij et al., 2009]. However, the early 
detection of AAS for assessment of 
cardiovascular risks (CVR) and effective 
prevention of cardiovascular events (CVE) 
presents serious difficulties [Boytsov et al., 2012; 
Kaptoge et al., 2014; Tarasov et al., 2017]. For 
example, the results of numerous studies indicate 
that the SCORE system, used to assess 
cardiovascular risks in a population, is not 
sufficiently informative; in particular, it does not 
reflect the presence of AAS which is typically 
associated with high or very high CVR [Kaptoge 
et al., 2014; Svistunov et al., 2018].  
 
At present, the link between atherogenesis and 
endothelial dysfunction (ED) has been well 
established. In development of atherosclerosis, a 
low-intensity systemic inflammation plays an 
important role [Libby and Crea, 2010; Tarasov et 
al., 2016, 2017]. In this regard, such diagnostic 
and prognostic aspects of key mechanisms as 
endogenous risk factors for CAD and metabolic 
disorders are being actively studied. In our 
previous studies, it has been found that 
atherosclerosis-associated vascular lesions are 
characterized by overexpression of circulating 
markers of ED, pro-inflammatory cytokines and 
antibodies to the connective tissue components 
of the vascular wall [de Rooij et al., 2009; 
Svistunov et al., 2018]. The degree of increase in 
the level of the studied parameters depends on 
the severity of the clinical form of CAD, the 
presence of macrovascular complications in 
T2DM, as well as on the combination of these 
diseases. At the same time, AAS is also 
characterized by the presence of the above 
mentioned specific biomarkers, which suggests 
the possibility of using them for improved 
diagnostics of diseases associated with 
atherosclerosis and CV complications. 
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In light of these previous findings, the objective 
of this study is to comprehensively assess the role 
of cytokine imbalance and antibody production 
to the components of the connective tissue in the 
development of CVE in AAS, CAD and T2DM 
patients in the absence and in the presence of 
metabolic disorders. 
 
Materials and methods 
 
A total of 393 patients divided into three groups 
participated in the study (Fig. 1). The first group 
consisted of 147 persons with clinical and/or 
instrumental signs of CAD. The second group 
included 126 persons suffering from T2DM. The 
third group included 120 AAS patients without 
clinical and instrumental signs of CAD and 
T2DM; they were diagnosed with AAS based on 
the results of instrumental studies that were 
additionally carried out during the screening 
process. People with symptomatic 
atherosclerotic lesions of other vascular pools, 
except the coronary one, were not included in the 
group of patients with CAD and T2DM.  
 
 
Figure 1. The study design. 
 
 
 
 
 
 
 
 
 
Throughout the entire observation period, 
patients with CAD and T2DM received a 
standard therapy according to the current 
national and international guidelines. Non-
pharmacological and medical (statins) 
prophylaxis of CAD was performed for 
individuals with AAS. We initially determined 
the basal levels of soluble ED markers  (von 
Willebrand factor (vWf), endothelin 1 (ET-1), 
endogenous NO synthase (eNOs)), auto-
antibodies (antibodies to hyaluronic acid (a-HA), 
chondroitin sulfate (a-ChS), collagen (a-Coll)), 
and indicators of pro-inflammatory cytokine 
panel (tumor necrosis factor-α (TNF-α), 
interleukin 1 and 6 (IL -1, IL-6)), using an 
enzyme immunoassay. After 3 years, 124 people 
from the CAD group, 108 patients with T2DM 
and 114 people with AAS completed the study. 
To assess the pathogenetic differences regarding 
the effect of ED markers and immune 
inflammation molecules on the progression of 
CVD, we identified 8 cohorts for comparative 
analysis (Fig. 2). 
 
To assess the role of the studied markers in the 
development and progression of atherosclerotic 
angiopathy, 2 cohorts were formed: cohort 1 
included individuals with established AAS, and 
cohort 2 included patients with CAD. To assess 
the relationships between the studied markers 
and the atherosclerosis stage (preclinical or 
clinical), regardless of the presence of 
carbohydrate metabolism disorders, we 
examined cohort 3, which included patients with 
T2DM and AAS, and cohort 4 which consisted of 
patients with CAD and T2DM. To clarify the 
relationship of metabolic disorders and insulin 
resistance with the development of CVD and to 
analyze the role of the studied markers in this 
process, cohorts 5-8 were formed: cohort 5 
included the patients from AAS group in 
combination with MS; cohort 6 – the group of 
patients with AAS but without MS; cohort 7 
included patients with CAD in combination with 
MS; cohort 8 consisted of persons with CAD 
without MS. For a more objective assessment of 
pathogenic features of ED and immune 
inflammation in the presence of chronic 
hyperglycemia, it was important to conduct two 
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additional pairwise comparative analyses. 
Specifically, we compared cohort 3 (patients with 
T2DM without CAD) and cohort 1 (persons with 
AAS without T2DM); and, finally, we compared 
cohort 4 (patients with CAD in combination with 
T2DM) and cohort 2 (patients with CAD without 
T2DM). 
 
 
Figure 2. Cohorts of patients formed to assess the role of the studied markers in the development 
and progression of CAD, T2DM and AAS with and without MS. 
 
For cluster analysis, we used the following 
laboratory parameters as independent variables 
(predictors): pro-inflammatory cytokines, 
markers of ED, autoantibodies, high-sensitivity 
C-reactive protein (hs-CRP), and an indicator of 
endothelial function, determined by 
photoplethysmometric method (EFI-EF Index). 
We analyzed the clinical outcomes for patients 
over a three-year period of prospective 
observation as dependent variables, which were 
set as semi-continuous score values from 0 to 
4depending on the nature of the complications 
from negligible to fatal: 0 - no adverse events for 
3 years; 1 - manifestation of a chronic form of 
CAD; 2 -manifestation of acute coronary 
syndrome (ACS); 3 - death. With multiple 
endpoints in cluster analysis, we took into 
account the most adverse event. We used a K-
means clustering algorithm with the number of 
iterations 50; the number of clusters (k) was 
determined empirically, based on the task to 
allocate a cluster of people with the highest 
frequency and severity of unfavorable 
cardiovascular events during the prospective 
observation period for the purpose of 
comparative assessment of the studied markers. 
 
Results and discussion 
 
As a result of the pairwise comparisons in the 
studied cohorts, we obtained from 2 to 4 clusters, 
each of which was characterized by a certain 
profile of the studied biomarkers. The centroids 
of the mean values of the studied parameters in 
clusters of patients from the comparison cohorts 
are presented in Table 1.  
 
Among the patients with AAS we have 
distinguished 3 clusters. In terms of the 
frequency and severity of CVE, cluster 1 and 
cluster 2 did not have significant differences, 
while cluster 3 differed significantly from 
clusters 1 and 2 (more advanced disease). Cluster 
3 (Table 1) was characterized by ED (high levels 
of ET-1, vWf and low levels of eNOS), 
significant deviations of the cytokine panel 
(elevated levels of IL-1β and TNF-α) and high 
levels of antibodies to C I and III types, a-ChS 
and a-HA. Cluster 3 was also characterized by 
higher values of hs-CRP and lower values of EFI, 
although the differences in these indicators 
between the clusters were insignificant. Among 
the patients with CAD in the absence of DM, we 
identified 4 clusters. The greatest frequency and 
severity of CVE was observed in cluster 1 (Table 
1). It was characterized by pronounced ED (high 
ET-1 and vWf, and minimal concentration of 
NOs) in combination with moderate 
hypercytokinemia and increased levels of 
antibodies to connective tissue antigens. 
 
Among the patients with T2DM without CAD 2 
clusters were distinguished, whereas among 
T2DM/CAD persons, 3 clusters were identified. 
In T2DM without CAD, a high frequency of CV 
events was observed in cluster 1. In this cluster 
(Table 1) we did not find any signs of a true ED 
(high levels of ET-1 and vWf, and low levels of 
 
 
 
66 
Encuentre este artículo en http://www.udla.edu.co/revistas/index.php/amazonia-investiga o www.amazoniainvestiga.info                
ISSN 2322- 6307 
eNOS and EFI), systemic inflammatory response 
with a significant increase in TNF-α and IL-6, as 
well as more active production of autoantibodies 
to C I, III types and a-HA. In the cohort of 
patients with CAD combined with T2DM, 3 
clusters were identified. The highest frequency of 
adverse CVE was observed in cluster 3 (Table 1), 
which was characterized by higher levels of ET-
1, vWf, TNF-α, as well as overexpression of 
autoantibodies to HA. In patients with AAS in the 
presence and absence of MS 3 clusters of patients 
were identified. Among the patients with AAS 
with MS, the adverse CVE more often developed 
in cluster 2, which was characterized by 
pronounced immune-mediated inflammatory 
changes with the maximal values of all pro-
inflammatory cytokines (IL-1β, TNF-α and IL-6) 
and autoantibodies (anti-C, anti-CS and anti-
HA), with moderate ED by type of activation. 
Among the patients with AAS without MS, the 
adverse CVE more often developed in cluster 3, 
which was characterized by a higher level of 
antibodies to all components of the connective 
tissue, a significant increase in IL-6 and a 
moderately pronounced ED. Among the 
CAD/MS patients, 2 clusters were distinguished, 
while among the patients with CAD in the 
absence of MS, 3 clusters were identified. In the 
first case, the highest incidence and severity of 
adverse CVE occurred in patients in cluster 2 
(Table 1), which was characterized by 
pronounced activation of endothelium with 
overexpression of ET-1 and vWf. In the same 
cluster, the marked immune-mediated 
inflammatory shifts were observed with the 
increase in all pro-inflammatory cytokines and 
production of autoantibodies to the components 
of the connective tissue, primarily to C types I 
and III. 
 
 
Table 1. Centroids of average values of the studied parameters in cohorts of patients with AAS and 
CAD (1 pair), type 2 diabetes with CAD and without CAD (2 pairs), AAS with MS and without MS, 
and CAD with and without MS. 
 
 
 
 
 
Cl
ust
er 
Centroids for k-means clustering (AAS (no DM)) 
Number of clusters: 3 
Total number of training cases: 114 
ET-
1 
v
Wf 
eNO
s 
IL-
1 
T
NF 
IL-
6 
a-
Coll 
a-
ChS 
a-
HA 
EF
I 
C
RP 
Eve
nts 
Num
ber of 
cases 
Percentag
e(%) 
1 
1.63
809
5 
1.7
25
71
4 
280.
309
5 
52.
45
23
8 
14.
64
28
6 
9.0
47
62 
0.19
476
2 
1.37
381
0 
1.71
738
1 
18.
26
19
0 
3.3
33
33
3 
0.21
428
6 
42 36.84211 
2 
0.73
390
2 
0.8
71
70
7 
355.
000
0 
76.
17
07
3 
21.
75
61
0 
14.
70
73
2 
0.21
829
3 
1.56
829
3 
1.73
317
1 
18.
02
43
9 
3.2
80
48
8 
0.34
146
3 
41 35.96491 
3 
1.25
806
5 
1.6
49
03
2 
385.
580
6 
92.
96
77
4 
23.
67
74
2 
11.
83
87
1 
0.28
838
7 
2.21
935
5 
2.64
935
5 
17.
70
96
8 
3.4
35
48
4 
1.83
871
0 
31 27.19298 
 
 
 
 
Cl
ust
er 
Centroids for k-means clustering (CAD (no DM)) 
Number of clusters: 4 
Total number of training cases: 124 
ET-
1 
v
Wf 
eNO
s 
IL-
1 
T
NF 
IL-
6 
a-
Coll 
a-
ChS 
a-
HA 
EF
I 
C
RP 
Eve
nts 
Num
ber of 
cases 
Percentag
e(%) 
1 
4.75
500
0 
1.8
00
00
0 
151.
450
0 
10
5.0
50
0 
22.
95
00
0 
21.
85
00
0 
0.24
150
0 
2.27
000
0 
3.03
500
0 
0.5
00
0 
4.1
55
00
0 
1.50
000
0 
20 16.12903 
2 
5.95
625
0 
1.6
81
230.
375
0 
10
2.5
19.
75
36.
68
0.40
625
0 
2.56
250
0 
3.50
000
0 
-
11.
5.1
68
0.81
250
0 
16 12.90323 
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1 
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4 
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23.
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17
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00
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411
8 
3.00
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2 
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4.2
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05
9 
0.00
000
0 
17 13.70968 
4 
3.52
112
7 
1.5
98
59
2 
310.
267
6 
85.
49
30 
18.
38
02
8 
23.
49
29
6 
0.20
380
3 
1.99
859
2 
2.23
943
7 
9.5
77
5 
4.0
18
31
0 
0.23
943
7 
71 57.25806 
 
 
 
 
Cl
ust
er 
Centroids for k-means clustering (DM+AAS) 
Number of clusters: 2 
Total number of training cases: 32 
ET-
1 
v
Wf 
eNO
s 
IL-
1 
T
NF 
IL-
6 
a-
Coll 
a-
ChS 
a-
HA 
EF
I 
C
RP 
Eve
nts 
Num
ber of 
cases 
Percentag
e(%) 
1 
1.62
250
0 
4.8
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5 
18
1.1
87
5 
38.
31
25
0 
35.
31
25
0 
0.33
312
5 
1.76
875
0 
3.35
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5 
-
6.2
50
00 
4.5
56
25
0 
1.93
750
0 
16 50.00000 
2 
1.05
562
5 
4.7
25
00
0 
260.
875
0 
17
4.4
37
5 
35.
81
25
0 
25.
18
75
0 
0.23
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0 
1.85
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0 
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437
5 
2.6
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5.2
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0 
0.25
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0 
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Cl
ust
er 
Centroids for k-means clustering (DM+CAD) 
Number of clusters: 3 
Total number of training cases: 76 
ET-
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v
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IL-
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T
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IL-
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a-
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a-
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8 
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0.6
95
7 
35.
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04
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0.34
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3 
2.28
695
7 
3.53
347
8 
-
8.4
78
3 
5.3
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5 
1.34
782
6 
23 30.26316 
 
 
 
 
Cl
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er 
Centroids for k-means clustering (AAS+МS) 
Number of clusters: 3 
Total number of training cases: 83 
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ust
er 
Centroids for k-means clustering (AAS+MS) 
Number of clusters: 3 
Total number of training cases: 83 
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er 
Centroids for k-means clustering (CAD+MS) 
Number of clusters: 2 
Total number of training cases: 90 
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Centroids for k-means clustering (CAD (no MS)) 
Number of clusters: 3 
Total number of training cases: 34 
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Among the patients with CAD in the absence of 
MS, a high incidence of CVE was observed in 
clusters 2 and 3. In these clusters (Table 1), the 
signs of pronounced ED and hyperproduction of 
pro-inflammatory cytokines and the studied 
autoantibodies were found. Cluster 2 with the 
most unfavorable disease progression was 
characterized by the highest rates of a-Chs and a-
HA and the maximal level of IL-1β. 
 
 
 
Figure 3. Centroids of average values of the investigated parameters in cohorts of patients with 
AAS and CAD (1 pair), type 2 diabetes with CAD and without CAD (2 pairs), AAS with MS and 
without MS, and CAD with and without MS. 
 
 
As a result of the cluster analysis, we were able 
to assess the contribution of each of the studied 
parameters to the development of adverse CVE 
and to identify the profile of ED and immune 
inflammation circulating markers reflecting the 
frequency and severity of CV complications 
depending on the stage of atherosclerosis (AAS 
or clinically manifested coronary 
atherosclerosis), and also the presence of 
disorders of carbohydrate metabolism (metabolic 
syndrome or T2DM). Schematically, the data are 
summarized in Fig. 3. 
 
As follows from these data, the greatest 
contribution to the development of CVE in 
patients with AAS without T2DM is made by 
circulating markers of ED and immune 
inflammation, such as ET-1, IL-1β, TNF-α, 
autoantibodies to C I and III, and CS. In patients 
with CAD without T2DM, ET-1, eNOs, 
antibodies to collagen, as well as IL-6 and vWf 
are the key contributors. In patients with T2DM 
without CAD, the set of markers associated with 
the development of adverse events includes ET-
1, eNOs, IL-6, anti-C, and anti-HA, whereas in 
T2DM/CAD patients, this profile includes the 
reduced level of eNOs, the increased levels of 
vWf, TNF-α, IL-6, hs-CRP, and overexpression 
of antibodies to C and HA. In AAS/MS patients, 
along with hs-CRP, the key contributors are the 
increased levels of IL-1β, TNF-α, and antibodies 
to C, CS, HA. The development of CVE in the 
group with AAS but without MS is associated 
with the increased level of circulating markers of 
ED (ET-1, vWf), as well as antibodies to C and 
CS. 
 
Obtained data are in consent with the results of 
numerous investigations which had 
demonstrated predictive value of the pro-
inflammatory markers basal levels in CVE 
[Mueller, 2014; Ridker, 2014]. It was shown that 
increased levels of ‘upstream’ markers such as 
IL-6, IL-18 and TNF-α were all associated with 
future vascular events in an approximately log-
linear manner, as were level of matrix 
metalloproteinase-9. However the magnitudes of 
these effects were smaller than that associated 
with the ‘downstream’ inflammatory biomarker, 
CRP. Since inflammation plays a key role in 
atherosclerotic plaque formation and further 
plaque destabilization biomarkers of plaque 
instability are logical candidates for early 
diagnosis of atherosclerotic CVD. Recent studies 
have shown that available assays for detection of 
these markers including myeloperoxidase, 
myeloid-related protein 8/14, pregnancy-
associated plasma protein-A, and CRP have very 
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low diagnostic accuracy and therefore are not 
helpful in the early diagnosis of CVE. In this 
context searching for additional markers 
reflecting plague instability such as anti-
connective tissue antibodies and/or ED agents 
seems to be appropriate for diagnostic and 
prognostic purposes. 
 
Conсlusion 
 
The obtained results confirm the modern 
inflammatory concept of atherosclerosis and 
suggest that the mechanisms of immune 
inflammation play an important pathogenic role 
in the development of atherosclerosis and CAD, 
as well as in the development of vascular 
complications in clinically significant metabolic 
disorders such as MS and T2DM. It has been 
established that the contribution of immune 
inflammation and ED to the development of CV 
complications depends on the stage of the 
atherosclerotic process and the severity of 
carbohydrate metabolism disorders. The most 
typical profiles of the studied biomarkers, 
reflecting a high risk of adverse CVE in AAS, 
СAD, T2DM, and MS, as well as in a 
combination of atherosclerosis and carbohydrate 
metabolism disorders, were identified. The 
obtained data are of practical interest in 
connection with the possibility of their use for 
predicting CV complications in high-risk 
patients. 
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